Daniel Rehling
Overview
Explore the profile of Daniel Rehling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
73
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valerie N, Sanjiv K, Mortusewicz O, Zhang S, Alam S, Pires M, et al.
Nat Commun
. 2024 Dec;
15(1):10347.
PMID: 39643609
Cellular target engagement technologies enable quantification of intracellular drug binding; however, simultaneous assessment of drug-associated phenotypes has proven challenging. Here, we present cellular target engagement by accumulation of mutant as...
2.
Rehling D, Scaletti E, Rozman Grinberg I, Lundin D, Sahlin M, Hofer A, et al.
Biochemistry
. 2021 Dec;
61(2):92-106.
PMID: 34941255
Ribonucleotide reductase (RNR) is an essential enzyme with a complex mechanism of allosteric regulation found in nearly all living organisms. Class I RNRs are composed of two proteins, a large...
3.
Nishii R, Mizuno T, Rehling D, Smith C, Clark B, Zhao X, et al.
Nat Commun
. 2021 Jul;
12(1):4181.
PMID: 34234136
Nucleobase and nucleoside analogs (NNA) are widely used as anti-viral and anti-cancer agents, and NNA phosphorylation is essential for the activity of this class of drugs. Recently, diphosphatase NUDT15 was...
4.
Zhang S, Rehling D, Jemth A, Throup A, Landazuri N, Almlof I, et al.
Cell Chem Biol
. 2021 Jun;
28(12):1693-1702.e6.
PMID: 34192523
Ganciclovir (GCV) is the first-line therapy against human cytomegalovirus (HCMV), a widespread infection that is particularly dangerous for immunodeficient individuals. Closely resembling deoxyguanosine triphosphate, the tri-phosphorylated metabolite of GCV (GCV-TP)...
5.
Rehling D, Zhang S, Jemth A, Koolmeister T, Throup A, Wallner O, et al.
J Biol Chem
. 2021 Mar;
296:100568.
PMID: 33753169
The enzyme NUDT15 efficiently hydrolyzes the active metabolites of thiopurine drugs, which are routinely used for treating cancer and inflammatory diseases. Loss-of-function variants in NUDT15 are strongly associated with thiopurine...
6.
Zhang S, Desroses M, Hagenkort A, Valerie N, Rehling D, Carter M, et al.
Nat Chem Biol
. 2020 Jul;
16(10):1120-1128.
PMID: 32690945
The NUDIX hydrolase NUDT15 was originally implicated in sanitizing oxidized nucleotides, but was later shown to hydrolyze the active thiopurine metabolites, 6-thio-(d)GTP, thereby dictating the clinical response of this standard-of-care...
7.
Valerie N, Hagenkort A, Page B, Masuyer G, Rehling D, Carter M, et al.
Cancer Res
. 2016 Aug;
76(18):5501-11.
PMID: 27530327
Thiopurines are a standard treatment for childhood leukemia, but like all chemotherapeutics, their use is limited by inherent or acquired resistance in patients. Recently, the nucleoside diphosphate hydrolase NUDT15 has...